Kate Bingham is the former Chair of the UK Vaccine Taskforce, where she led a team of world-class experts from across industry, science, academia and government with the shared purposed of finding and manufacturing COVID-19 vaccine/s. The Vaccine Taskforce helped place the UK at the leading edge of the international effort to fight the pandemic and the UK was the first Western country to start vaccination in December 2020.
Kate has worked in the biotech sector for 30 years and is Managing Partner at life sciences venture capital firm SV Health Investors, where she is responsible for SV’s biotech investments. Her investments have led to the launch of six drugs for the treatment of patients with inflammatory and autoimmune disease and cancer.
Kate is a board member of the Francis Crick Institute. She won the Lifetime Achievement Award, presented by the BioIndustry Association UK in January 2017 and has a first class degree in Biochemistry from the University of Oxford and an MBA from Harvard Business School (Baker Scholar).